On May 12, 2025 Elpis Biopharmaceuticals, a clinical-stage cell therapy company developing bispecific armored CAR-T therapies for solid tumors, reported that Founder and CEO Yan Chen, MD, PhD, will present new preclinical data on the company’s proprietary multi-mechanism armored CAR-T platform at the PEGS Protein & Antibody Engineering Summit on May 14, 2025, in Boston (Press release, Elpis Biopharmaceuticals, MAY 12, 2025, View Source [SID1234652894]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
In the presentation, "Multi-Mechanism Armored CAR-T Effectively Overcomes Tumor Microenvironment Resistance and Eradicates Solid Tumors," Dr. Chen will highlight the discovery of Elpis’s multi-mechanism armor by fusing a precision-engineered IL-2 molecule to an anti-PD-L1 antibody, which has the potential to simultaneously overcome multiple resistance mechanisms within the tumor microenvironment (TME). The platform is designed to activate bystander immune cells, selectively target key immune cell types, and orchestrate the immune system for a durable anti-tumor response.
Elpis’s human bispecific armored CAR-T cells have demonstrated potent tumor regression, long persistence, and robust immune modulation across multiple solid tumor models—all at significantly lower doses. These attributes reflect the platform’s potential to improve drugability, safety and support more durable clinical outcomes.
"This is an exciting moment for Elpis," said Dr. Chen. "Our multi-mechanism armor is the result of years of innovation in precision cytokine engineering empowered by mRNA display technology. By addressing both TME resistance with armored cytokine and tumor heterogeneity through bispecific targeting, our platform has the potential to deliver safer, more effective and persistent CAR-T therapies in solid tumors."
Event:
PEGS Summit, Omni Boston Hotel
Session Title:
Multi-Mechanism Armored CAR-T Effectively Overcome Tumor
Microenvironment Resistance and Eradicate Solid Tumors
Session Date:
Wednesday, May 14, 12:30 pm ET
Presenter:
Dr. Yan Chen, Founder and CEO, Elpis Biopharmaceuticals